Healthy person
Conditions
Interventions
Intake the test food (CogniUp capsule) for 12 weeks
Intake the control food for 12 weeks
Sponsors
Akanuma surgical clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Consent for participation in study Japanese men and women aged between 20 and under 80 2) Not applicable to the diagnostic criteria for dementia 3) Person who feels more forgetful than before 4) People who are healthy and are not currently treating any serious disease 5) Persons who can visit a designated medical institution on the scheduled arrival date 6) Those who agreed in writing after fully understanding the purpose and contents of this exam
Exclusion criteria
Exclusion criteria: 1) Persons who regularly use health foods (including antioxidant effects, supplements with blood flow revision effect, etc.) intended to reduce brain function or forgetfulness 2) Persons who are difficult to participate in the examination due to liver, kidney, heart disease, respiratory disorder, endocrine disorder, metabolic disorder, neurological disorder, disturbance of consciousness, diabetes (according to the criteria established by the Japan Diabetes Association), epileptic seizures, 3) Treatment with stroke, subarachnoid hemorrhage, cerebral infarction, cerebral hemorrhage, brain contusion, head injury Inpatient surgery Those who have things 4) taking medications (such as antipsychotic drugs, anxiolytics, antidepressants, antiparkinsonism drugs, antidepressants, antiepileptic drugs, anticoagulant drugs, etc.) that are likely to affect the results of this study Who 5) Persons who are allergic to test foods 6) History of hepatitis, those with current medical history, cardiovascular disease, those with advanced anemia 7) Persons who have experienced a feeling defect or physical condition deterioration due to blood sampling in the past 8) Those who donated 200 mL or more from the beginning of the test until the start of the test or those who have the schedule during the test period 9) Participating in other clinical trials or within 4 weeks after the exam 10) Alcohol drinkers and excessive smokers 11) Extremely irregular eating habits 12) A person who can not agree with the purpose of this test conducted in advance 13) Those who have received neuropsychological tests etc. within the hospital within the past 3 months 14) Person who judged that examination responsible doctor is not appropriate for this study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy: FDG-PET, Cognytrax Safety: Side effect occurrence rate Evaluation period: 0, 6, 12 weeks * 1, FDG-PET is measured after screening test and intake for 12 weeks * 2, Cognytrax is measured after screening test and 0, 6, 12 weeks ingestion | — |
Secondary
| Measure | Time frame |
|---|---|
| Effectiveness: Questionnaire Safety: Adverse event incidence Evaluation period: 0, 6, 12 weeks | — |
Countries
Japan
Contacts
Public ContactMegumi Takahashi
Ryusendo Co., Ltd. Development Office
Outcome results
None listed